|
Thank you for your interest in this Ca De Bou Breeder Wanted Ad. By filling out the information request form below you will be able to make contact with this advertiser. We appreciate the time that you are taking now in order to possibly help fulfill this individuals request.
| Re: | Ca De Bou Breeder Wanted | | Ad: | Special Delivery http://livejasmin.in.net/ jasminelive Afatinib's safety and effectiveness were evaluated in clinical studies involving 345 people with spreading NSCLC whose tumors had EGFR mutations. Among those who received afatinib, progression-free survival was 4.2 months longer than for those who received chemotherapy, the FDA said. There was no statistically significant difference in overall survival, the agency added.
|
|